

Material and Methods: About 225 patients (mean age 45 ± 6 years) presenting with variable morphology, histological grades and clinical stage of the breast carcinomas during January 2006 to January 2008 were included. The patients were assessed both clinically as well as expression of ER, PR and NE markers was determined by indirect immunohistochemistry. Positive staining was asserted following the criterion proposed in previous literature. The patients were followed up clinically from the departmental record for 3 years till January 2011.

Results: The findings of our study revealed that immunohistochemical staining of the histological tissue sections of 10.2%, 7.4% and 15.1% breast carcinomas demonstrated focal areas with mild to strong cytoplasmic staining of the tumour cells by CgA, NSE and HDC respectively. Individual subtypes when assessed revealed that most of the ductal carcinomas stained positively and strongly than other varieties. Our findings also depicted that HDC expression in detecting the NE foci in breast carcinomas was stronger and more sensitive than CgA and NSE ($P = 0.0063$) and that too even in PD tumours of which 8.2% were strongly positive as compared to CgA (2.0) and NSE (1.3%) ($P < 0.001$). No significant association was found between the NED of breast carcinomas and clinico-pathological or hormonal receptor status of the patients. As per the follow-up record of 3 years, either univariately nor taking account of various known prognostic factors, does focal NED appear to carry a special prognostic significance as disease recurrence occurred locally in 01 patient and distant metastases was found in none.

Conclusion: Our results suggest that NED, though present in breast carcinomas, particularly of ductal type, may characterize a subgroup of these tumours with no significant impact on patient prognosis. However, more perspective analyses with prolonged follow up should be carried out in our female patients to assess these NE differentiated carcinomas in terms of their prognostic implication and therapeutic choices.

176

Poster

Impact in the Management of Patients After Pathology Second Opinion in Breast Cancer

V. Marco¹, T. Muntal¹, J. Cortes², B. Gonzalez², I.T. Rubio². ¹Department of Pathology. Hospital Quirón, Barcelona, Spain; ²IOB. Hospital Quirón, Barcelona, Spain

Background: A second opinion in pathology may be requested by clinicians, when a patient is referred from another hospital for diagnosis and treatment. In patients with breast cancer, the pathology report contains valuable information about the diagnosis, but also related to prognosis and therapeutic response. We report the experience with second opinion in breast pathology, in selected patients consulting the Breast Oncology Unit at our institution.

Materials and Methods: Two hundred and four cases referred to the Breast Oncology Unit were selected for second opinion after clinical evaluation, between 2002 and 2011. The cases reviewed included 92 core needle biopsies, 98 surgical biopsies, and 14 fine needle aspiration cytologies. A case was classified as major change in second opinion when the findings had the potential for significant change in treatment or prognosis. A case was considered to represent minor change, when these did not alter significantly the treatment or prognosis.

Results: Concordant results were found in 162 (79.4%) diagnoses. In 42 cases (20.5%) the pathology review showed changes. Twenty-eight (13.2%) patients were classified as major changes. In 4 of this 28 patients, breast cancer metastasis diagnosed in an axillary node turned to be non mammary breast cancer (one was a melanoma, two were lung metastasis and one was a cutaneous anaxal tumor). Another patient with a diagnosis of breast cancer metastasis in a brain biopsy was changed to lung metastasis to the brain and the last one diagnosed as breast cancer was changed to lung metastasis in the breast. Two patients diagnosed with breast cancer changed to benign breast lesions. In 4 patients there was a change in estrogen receptor status, three from negative to positive, and one in the opposite way. The Her2-neu status changed from positive to negative in five cases. Five patients with a diagnosis of infiltrating ductal carcinoma (IDC) turned to be carcinoma in situ (DCIS) in three, and microinvasive in two. Four patients classified as DCIS changed to IDC, and two cases changed from microinvasive carcinoma to DCIS. Fourteen patients (6.8%) had minor changes after the pathology second opinion. Most of them included changes in atypical hyperplasia to typical. Others reviews resulted in changes in progesterone receptor status that did not change treatments.

Conclusions: Second opinion in breast pathology may uncover significant discrepancies that impact in patient management and prognosis. Major discrepancies are most frequently related to the assessment of the degree of invasion of breast carcinoma and the result of immunohistochemical studies. However, the assessment of axillary lesions and distant metastasis in patients suspected of having breast cancer that may reveal non-mammary tumors, together with the diagnosis of benign proliferative lesions that simulate malignancy, may also severely affect the patient's treatment and prognosis.

177

Poster

Ductal Carcinoma in Situ of the Breast – Modified Black Nuclear Grading System Revisited

F. Schuh¹, J.V. Biazús¹, J.A. Cavalheiro¹, C.C. Falcão¹, A.F. Ventura², E. Resetkova³, M.I. Edelweiss⁴. ¹Hospital de Clínicas de Porto Alegre (HCPA), Breast Unit, Porto Alegre, Brazil; ²Hospital São Cristóvão, Breast Unit, São Paulo, Brazil; ³The University of Texas – MD Anderson Cancer Center, Department of Pathology, Houston, USA; ⁴Hospital de Clínicas de Porto Alegre (HCPA), Department of Pathology, Porto Alegre, Brazil

Background: This study aims to determine the pathologists agreement of modified Black nuclear grading system and Holland classification applied to cases of ductal carcinoma *in situ* (DCIS) of the breast.

Materials and Methods: Forty-three cases of breast lesions diagnosed as DCIS were selected to interobserver analysis. Twelve pathologists received the same set of digitized images from microscopy of the DCIS cases, and answered a questionnaire containing the criteria to compose the modified Black nuclear grading system and Holland classification system. In order to determine interobserver agreement and diagnostic accuracy, a web-based survey was created. It organizes the information collected from each pathologist providing the histological grading of the cases in both classification systems.

Results: The reliability for the modified Black nuclear grade applied to cases of DCIS was acceptable, with Kappa value of 0.23 ± 0.02 . Comparing the two classification systems studied, there was a similar agreement among both schemes, showing Kappa value of 0.27 ± 0.03 for the Holland classification. Analyzing a subgroup of pathologists rated according to their interest in breast pathology, a higher diagnostic reproducibility was found for the group of breast pathology experts in relation to the pathology residents only for the modified Black nuclear grading system ($\kappa = 0.43 \pm 0.07$ vs. $\kappa = 0.11 \pm 0.05$; $p = 0.002$). The agreement among all pathologists and the gold standard pathologist similarly followed the results of the interobserver concordance, showing to be acceptable, with Kappa for the overall mode value 0.32 ± 0.10 for both classifications. The findings of Kappa for the mode values among specialists in breast pathology and pathology residents were, respectively, 0.34 ± 0.11 (acceptable) and 0.19 ± 0.08 (weak) for the modified Black nuclear grade and 0.33 ± 0.11 (acceptable) and 0.19 ± 0.08 (weak) for Holland classification.

Conclusions: Breast pathology specialists showed greater reproducibility than pathologists not devoted to this subject for both evaluated classification systems. The diagnostic accuracy was similar for the modified Black nuclear grading system and the Holland's classification system.

178

Poster

Histopathological Grading of Ductal Carcinoma in Situ of the Breast – Validation of a Web-based Survey Through Intraobserver Reproducibility Analysis

F. Schuh¹, J.V. Biazús¹, E. Resetkova², C.Z. Benficia³, A.F. Ventura⁴, D. Uchoa⁵, M. Graudenz⁵, M.I. Edelweiss⁵. ¹Hospital de Clínicas de Porto Alegre (HCPA), Breast Unit, Porto Alegre, Brazil; ²The University of Texas – MD Anderson Cancer Center, Department of Pathology, Houston, USA; ³Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil; ⁴Hospital São Cristóvão, Breast Unit, São Paulo, Brazil; ⁵Hospital de Clínicas de Porto Alegre (HCPA), Department of Pathology, Porto Alegre, Brazil

Background: This study aims to develop a method of systematic application of the diagnostic criteria that compose the histological grades of ductal carcinoma *in situ* (DCIS) of the breast through a questionnaire available in a website, and to determinate its reliability and applicability in clinical practice.

Materials and Methods: The most important criteria to grade DCIS lesions in histopathological bases were selected to compose the point scoring system according to their relevance to three different DCIS classifications. A software was created in order to be accessed through Internet, in website format (<http://mayer.art.br/cainsitu/site3>). This website offers a questionnaire containing the characteristics used to compose the three DCIS classification systems evaluated in our study, and also the digitized microscopy images of 43 DCIS cases selected. Three pathologists, who are specialists in breast pathology, analyzed the same set of digitized images in this web-based survey. In the first phase, they answered a questionnaire with the characteristics used to compose the modified Black nuclear grade system and the classification systems of Holland and Van Nuys. After at least 6 months, the pathologists read again the same images, but without the help of the questionnaire, indicating subjectively the diagnoses, using the grading system of their daily practice. The intraobserver agreement analysis was used to validate this innovative web-based survey.

Results: Overall, diagnostic reproducibility was similar for all systems of histologic grading, with kappa values of 0.57 ± 0.10 , 0.67 ± 0.09 and 0.67 ± 0.09 for Holland, Van Nuys classification and modified Black nuclear grade system, respectively.

Conclusions: The intraobserver diagnostic reproducibility of DCIS with the use of digital images and a point scoring system in a web-based survey compared to subjective analysis is moderate to good for Holland, Van Nuys and modified Black nuclear grade system. The use of this point scoring system does not appear to pose a major risk of presenting large (2-step) diagnostic disagreements. These findings indicate that the use of this web-based survey to grade objectively DCIS lesions is a promising, useful and a reliable diagnostic tool.

179

Poster

Biomarker (ER, PR, Her2 and Ki67) Testing On Core Needle Biopsy Specimens From Primary Breast Cancer – Their Usefulness and Limitations

H. Nagaoka¹, T. Takahashi¹, K. Endo¹, K. Sugitani¹, K. Nakagami¹, Y. Kim¹, Y. Yoshida¹, U. Ooki¹, J. Horiguchi², I. Takeyoshi². ¹Ogawa Redcross Hospital, Department of Surgery, Saitama, Japan; ²Gunma University, Department of Thoracic and Visceral Organ Surgery, Gunma, Japan

Background: Accurate evaluation of biomarker [estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor type 2 (Her2) and Ki67] status is important for primary breast cancer patients to determine their course of therapy. We usually obtained these information from core needle biopsy specimens (CNBs) preoperatively, but diagnostic differences between CNB and surgically resected specimens (SRs) was not available. We investigate the correlation of ER, PR, HER-2 and Ki67 status in the CNBs with those observed in SRs.

Methods: A total of 102 patients with invasive ductal carcinoma without preoperative therapy were included in this retrospective study. CNB was underwent with 16Gauge needle under ultrasound-guide and 3–5 specimens were taken. ER, PR, Her2 and Ki67 status were determined by immunohistochemistry in invasive margin of tumor. ER and PR (≥ 3 : Allred score), Her2 (score3: ASCO/CAP), Ki67 ($>14\%$: Ki67 labeling index) were evaluated as positive case.

Results: The sensitivity, specificity, accuracy were well enough in ER (70.8%, 94.4%, 87.2%), PR (74.2%, 95.8%, 87.8%), Her2 (97.2%, 83.3%, 96.2%) status, while but it seems to be worse in Ki67 (70.2%, 85.7%, 74.2%). We sought the factors which drive down the diagnostic rate, clinicopathological characteristics (age, tumor size, lymphnode status, histological grade) and the number of CNBs were not concerned their accuracy.

Conclusion: CNB can be useful for ER, PR and HER2 status determination, while its usefulness for Ki67 status is limited. We should use caution to evaluate tumor proliferation with CNBs.

180

Poster

Aurora Kinase-A and Ki67 Expression in Primary Breast Carcinomas and Corresponding Distant Metastases

A.M. Tokes¹, A.M. Szasz¹, I. Kenessey¹, L. Lukacs², J. Kulka¹.

¹Semmelweis University Budapest, 2nd Department of Pathology, Budapest, Hungary; ²Honvedkorhaz-AEK, Department of Radiology, Budapest, Hungary

Background: This study evaluated the expression of Aurora-kinase A (AURKA) and Ki67 in a set of primary breast carcinomas and corresponding distant metastases of different localizations.

Methods: Forty-six primary breast carcinomas and corresponding forty-six distant metastatic paraffin-embedded samples were analysed for AURKA and Ki67 expression by immunohistochemistry. Another set of twenty breast cancer cases with no recurrence on 10-year follow-up were also evaluated representing control cases.

Results: Among the primary tumours 27 developed bone metastases, two metastasized to lung, six to central nervous system (CNS) and 11 primary tumours gave multiple metastases. AURKA showed strong positive correlation with Ki67 expression ($P < 0.05$). Primary breast carcinomas developing metastases are characterized by significantly higher level of Ki67 ($P = 0.003$) expression compared to primary breast carcinomas without metastases. No statistically significant difference were observed ($P > 0.05$) in AURKA expression when comparing the two groups of primary breast carcinomas. No significant differences were observed in AURKA and Ki67 expression between primaries metastasizing to bone, CNS, lung or primaries with multiple metastatic sites. By analysing the distant metastases at different locations, significantly higher levels of AURKA and Ki67 were detected in CNS metastases compared with lung ($P = 0.036$, $P = 0.0065$, respectively) and bone metastases ($P = 0.003$, $P = 0.0001$,

respectively). AURKA overexpression in primary breast carcinomas was not associated with distant metastases free survival (DMFS) ($P < 0.676$), whereas higher Ki67 expression was significantly associated with shorter DMFS ($P < 0.0002$). Younger age (< 56 years) was also associated with shorter DMFS ($P < 0.00001$).

Conclusions: Ki67 index appears to distinguish a fraction of primary breast carcinomas with worse prognosis, being associated with shorter DMFS. The fact that significantly higher levels of AURKA and Ki67 were detected in CNS metastases compared with lung and bone metastases suggests that this group of patients might be suitable for future targeted therapies with Aurora-kinase A inhibitors.

Grant support: TAMOP-4.2.2/B-10/1–2010–0013, ETT-088–2009, MKOT-GSK-2010, Bolyai János fellowship 2009–2011.

181

Poster

Breast Carcinoma in Mexican Women, Molecular Subtypes Using Immunohistochemical Surrogate Markers

V. Pérez Sánchez¹, H.A. Maldonado-Mtz¹, D. De León Trenado¹, E. Bargalló Rocha², A. Stankov Dragan², A. Alvarado Miranda³, A. Ojeda Gaona¹, F. Lara Medina³. ¹Instituto Nacional De Cancerología, Patología, Mexico D.f, Mexico; ²Instituto Nacional De Cancerología, Cirugía De Tumores Mamaros, Mexico D.f, Mexico; ³Instituto Nacional De Cancerología, Oncología Médica, Mexico D.f, Mexico

Background: Breast cancer (BC) has been classified in five different 'molecular subtypes' by gene expression profiling (luminal A, luminal B, HER2, basal like and normal like). Some 'key' genes in these expression profiles have been routinely examined and reported by immunohistochemistry (IHC). There are few studies correlating tumor features and 'molecular subtypes' defined by IHC expression of these 'key' genes (referred as 'surrogate markers'). The aim of this study was to evaluate a molecular classification scheme based on IHC, and its correlation to tumor features in Mexican women (Mw) with BC.

Materials and Methods: Retrospective study of 478 Mw with ductal infiltrating BC. We assessed estrogen receptor (ER) and progesterone receptor (PR) employing HScore index. Her2 was evaluated according to ASCO/CAP guidelines. Ki-67 was recorded as percent of the positive tumor cells. Criteria for tumor classification are shown in the table. Clinical and pathologic features were compared. Data were analyzed with SPSS 17.

Category	Criteria used in this study
Luminal A (LUMA)	ER ≥ 200 , Her2 negative
Luminal B (LUMB)	ER 11–199 or PR >10 , Her2 negative
Her2	ER and PR ≤ 10 , Her2 positive
Triple negative (TPN)	ER and PR ≤ 10 , Her2 negative
Luminal A–Her2 hybrid (LAHH)	ER ≥ 200 , Her2 positive
Luminal B–Her2 hybrid (LBHH)	ER 11–199 or PR >10 , Her2 positive

Results: Tumors were classified as follows: LUMA 83 cases (17.4%), LUMB 166 (34.7%), Her2/neu 42 (8.8%), TPN 108 (22.6%), LAHH 18 (3.8%) and LBHH 61 (12.8%). Tumor size was greater in TPN and LUMB. High histological grade was more frequent in TPN (34.8%). Necrosis was more frequent in TPN than LUMA and LUMB ($p < 0.05$). Lymphoplasmacytic infiltrate was more common in TPN, Her2 and LAHH ($p < 0.05$). TPN, Her2 and LAHH showed higher Ki-67 index ($p < 0.05$). Metastasis to lymph nodes were more frequent in TPN and LUMB. LBHH, LAHH, Her2 and TPN were respectively the most frequent subtypes to develop metastases. LUMA was among the most frequent subtypes presenting at early stages, while TPN did so in late stages.

Conclusion: This is the first study on Mw that classifies BC according to 'molecular subtypes' by 'surrogate markers'. Tumor features related to different subtypes are concordant with previously reported data. In contrast with previous reports from other countries, we observed more frequently LUMB, LBHH and TPN in Mw. While a high proportion of TPN has been previously reported in Mw, this status for LUMB awaits for confirmation.